Gastric intestinal metaplasia (#GIM) is a histological finding which may identify pts at ⬆️ risk for Gastric AdenoCa. Follow our #tweetorial on quality metrics for #GIM management brought to you by the #AGAQuality team
May be ⬆️ in persons with specific genetic, environmental and #dietary risk factors
May be ⬇️ when specific testing & endoscopic surveillance strategies are followed
3/12
The most common type of gastric #cancer is intestinal-type, non-cardiac, which is usually associated w chronic #HPylori infection (80% of global burden) via stepwise mucosal changes: nml mucosa ➡️ chronic gastritis ➡️atropic gastritis ➡️ #GIM ➡️ Gastric AdenoCa
4/12
Risk factors for developing gastric #Cancer in pts w/ #GIM:
•Persistent #HPylori infection
•Family history of gastric #cancer
•Incomplete histological subtype
•Extensive #GIM
•Racial/ethnic minorities or immigrants from high incidence regions
Shared decision-making involving the patient and provider can determine need for #surveillence exams and should include:
✔️Overall gastric cancer risk
✔️Family history
✔️Patient preferences
7/12
If #surveillance biopsies are pursued, they should be taken from specific locations in the #stomach at an interval based on risk
8/12
GIM #AGAQUALITY MEASURE: All pts with #GIM should undergo assessment and eradication of #HPylori which includes confirmation of infection and follow up testing at least 4⃣ weeks after treatment completion